Search results
Added:
3 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis…
View more
Added:
6 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy…
View more
Staging of Heart Failure with Preserved Ejection Fraction
Added:
1 year ago
Expert Opinion
Added:
5 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Added:
9 months ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Added:
1 year ago
ESC Congress 2024 — FINEARTS-HF shows finerenone reduces cardiovascular death and total of worsening heart failure (HF) events over median follow-up of 32 months.Host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal investigator, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, US) to discuss findings from the landmark FINEARTS-HF trial (NCT04435626…
View more
Left Atrium Role in Secondary Mitral Regurgitation
Added:
1 year ago
Review Article
Added:
6 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the…
View more